Understanding how morphine affects bone health through microRNAs
Investigating miRNA-Mediated Bone Loss from Morphine Treatment
['FUNDING_FELLOWSHIP'] · MAINEHEALTH · NIH-11054549
This study is looking at how morphine, a common pain medication, might cause bone loss by exploring tiny molecules called microRNAs that affect bone health, using male mice to see how morphine changes bone density and these microRNAs, with the hope of finding ways to help people on opioids keep their bones strong.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAINEHEALTH (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-11054549 on ClinicalTrials.gov |
What this research studies
This research investigates how morphine treatment can lead to bone loss by examining the role of microRNAs, which are small molecules that regulate gene expression. The study uses a model where male mice are treated with morphine to observe changes in bone density and the expression of specific microRNAs associated with bone health. By understanding the mechanisms behind morphine's impact on bone, the research aims to uncover potential pathways that could be targeted to prevent bone loss in patients using opioids.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are using opioids for pain management and are at risk of bone density loss.
Not a fit: Patients who are not using opioids or those with pre-existing severe bone conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preserving bone health in patients who require opioid treatment.
How similar studies have performed: While the specific approach of examining microRNAs in the context of opioid-induced bone loss is novel, related research has shown that understanding molecular mechanisms can lead to significant advancements in treatment strategies.
Where this research is happening
PORTLAND, UNITED STATES
- MAINEHEALTH — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LANGLAIS, AUDRIE — MAINEHEALTH
- Study coordinator: LANGLAIS, AUDRIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: addictive disorder